Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products. The company’s therapeutic program is focused on developing new drugs that can improve outcomes, extend survival, and improve the overall quality of life. The goal of the diagnostic program is to develop products that will enable earlier detection, and the potential for earlier intervention. Our current clinical trials are directed toward patients with late-stage pancreatic and colorectal cancer.
One of the most important steps in the product development process is the clinical trials, in which cancer patients volunteer to receive experimental therapy and be observed for its effects.
Precision Biologics posts information for all ongoing Precision Biologics sponsored trials to the National Institutes of Health’s (“NIH”) ClinicalTrials.gov website. To learn more about the Precision Biologics clinical trials that are underway or to find out if a study is enrolling patients in your area, please click here. The institutions conducting the trials may also provide information on their web sites.
Precision Biologics posts protocol information for all ongoing Precision Biologics sponsored trials to the National Institutes of Health’s (“NIH”) ClinicalTrials.gov web site
More information on cancer and its management can be found at the websites of these organizations:
“Our monoclonal antibodies have the ability to act as a companion diagnostic platform to our therapeutic program by recognizing the tumor specific antigen that our therapeutic antibody targets and determine which patients are a candidate to receive treatment.”
Philip M Arlen, MD
Chief Executive Officer